You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, May 2018
|
| DOI | 10.1186/s40425-018-0362-6 |
| Pubmed ID | |
| Authors |
Ryan J. Sullivan, Michael B. Atkins, John M. Kirkwood, Sanjiv S. Agarwala, Joseph I. Clark, Marc S. Ernstoff, Leslie Fecher, Thomas F. Gajewski, Brian Gastman, David H. Lawson, Jose Lutzky, David F. McDermott, Kim A. Margolin, Janice M. Mehnert, Anna C. Pavlick, Jon M. Richards, Krista M. Rubin, William Sharfman, Steven Silverstein, Craig L. Slingluff, Vernon K. Sondak, Ahmad A. Tarhini, John A. Thompson, Walter J. Urba, Richard L. White, Eric D. Whitman, F. Stephen Hodi, Howard L. Kaufman |
| Abstract |
Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination regimens for patients with melanoma. However, prospective data to support evidence-based clinical decisions with respect to the optimal schedule and sequencing of immunotherapy and targeted agents, how best to manage emerging toxicities and when to stop treatment are not yet available. To address this knowledge gap, the Society for Immunotherapy of Cancer (SITC) Melanoma Task Force developed a process for consensus recommendations for physicians treating patients with melanoma integrating evidence-based data, where available, with best expert consensus opinion. The initial consensus statement was published in 2013, and version 2.0 of this report is an update based on a recent meeting of the Task Force and extensive subsequent discussions on new agents, contemporary peer-reviewed literature and emerging clinical data. The Academy of Medicine (formerly Institute of Medicine) clinical practice guidelines were used as a basis for consensus development with an updated literature search for important studies published between 1992 and 2017 and supplemented, as appropriate, by recommendations from Task Force participants. The Task Force considered patients with stage II-IV melanoma and here provide consensus recommendations for how they would incorporate the many immunotherapy options into clinical pathways for patients with cutaneous melanoma. These clinical guidleines provide physicians and healthcare providers with consensus recommendations for managing melanoma patients electing treatment with tumor immunotherapy. |
X Demographics
The data shown below were collected from the profiles of 31 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 11 | 35% |
| Mexico | 2 | 6% |
| Spain | 2 | 6% |
| Singapore | 1 | 3% |
| Romania | 1 | 3% |
| Ireland | 1 | 3% |
| Turkey | 1 | 3% |
| Unknown | 12 | 39% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 18 | 58% |
| Practitioners (doctors, other healthcare professionals) | 9 | 29% |
| Scientists | 3 | 10% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 110 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 110 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 24 | 22% |
| Other | 13 | 12% |
| Student > Master | 10 | 9% |
| Student > Bachelor | 10 | 9% |
| Professor | 8 | 7% |
| Other | 22 | 20% |
| Unknown | 23 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 42 | 38% |
| Agricultural and Biological Sciences | 8 | 7% |
| Biochemistry, Genetics and Molecular Biology | 7 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
| Nursing and Health Professions | 4 | 4% |
| Other | 10 | 9% |
| Unknown | 34 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 413. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 May 2019.
All research outputs
#71,344
of 25,461,852 outputs
Outputs from Journal for Immunotherapy of Cancer
#18
of 3,436 outputs
Outputs of similar age
#1,590
of 344,481 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 44 outputs
Altmetric has tracked 25,461,852 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,436 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.7. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 344,481 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 44 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.